BDNF, TNFα, HSP90, CFH, and IL-10 Serum Levels in Patients with Early or Late Onset Alzheimer's Disease or Mild Cognitive Impairment
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Identifying early-detection biomarkers have become an increasingly important approach in the treatment and prevention of Alzheimer's disease (AD). In this study, we investigated the potential of brain-derived neurotrophic factor (BDNF), complement factor H (CFH), tumor necrosis factor-α (TNFα), interleukin 10 (IL-10), and heat shock protein 90 (Hsp90) as serum biomarkers for AD in a cohort of the Turkish population because they have been suggested to be associated with AD. Serum BDNF, CFH, TNFα, IL-10, and Hsp90 levels in three groups of patients, early-onset AD (EOAD; age of onset 65; n = 54), and mild cognitive impairment (MCI) (n = 30), were compared with age-matched healthy controls (age 65; n = 32) using ELISA. The serum BDNF levels significantly decreased and TNFα levels significantly increased in the EOAD and LOAD groups compared to the age-matched healthy controls. There was a correlation between serum TNFα and IL-10 levels in the LOAD and healthy control groups. Serum CFH levels in the LOAD and MCI patients were significantly decreased compared with controls. Serum Hsp90 levels in the EOAD, LOAD, and MCI patients were significantly decreased compared with controls. The protein misfolding, the inflammatory response, and decreased neurotrophic factor synthesis are all suggested to be related to AD type brain pathology, and our results indicate these alterations might be traced from serum samples. For accurate early diagnosis of AD, it is important to determine a profil…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“as well as in AD patients’ CSF and serum [215,216,217,218,219,220,221,222]”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [221]
In the citing paper
“In humans, two studies have shown an increase in pro-inflammatory cytokines and a decrease in BDNF levels in the serum of early- and late-onset AD, although there was no correlation with pro-inflammatory and neurotrophin results in both studies [141, 156].”
From Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation (2019) · cites this paper as [141]
In the citing paper
“BDNF levels are also reduced in plasma of patients with mild cognitive impairment (MCI) [140] and AD [141].”
From Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation (2019) · cites this paper as [141]
Citations
Cites
Potential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867 · cited 1×
“…plasticity, neuronal neuronal survival, and differentiation, where it participates BDNF mRNA and protein levels in the hippocampus and neocortex of AD patients suggest that BDNF of BDNF have been reported in the hippocampus [9 and BDNF can mediate rapid dephosphorylation of tau protein [4].”
Brain-derived neurotrophic factor is reduced in Alzheimer's disease
Connor, B., Young, D., Yan, Q., Faull, R. L. M., Synek, B., & Dragunow, M. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00125-3 · Cited by 581
New insights into brain BDNF function in normal aging and Alzheimer disease
Tapia-Arancibia, L., Aliaga, E., Silhol, M., & Arancibia, S. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.07.007 · Cited by 571
Proteome-based plasma biomarkers for Alzheimer's disease
Hye, A., Lynham, S., Thambisetty, M., Causevic, M., Campbell, J., Byers, H. L., Hooper, C., Rijsdijk, F., Tabrizi, S. J., Banner, S., et al. (2006) · Brain · doi:10.1093/brain/awl279 · Cited by 464
Heat Shock Proteins 70 and 90 Inhibit Early Stages of Amyloid β-(1–42) Aggregation in Vitro
Evans, C. G., Wisén, S., & Gestwicki, J. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606192200 · Cited by 382 · cited 1×
“Studies suggest that chaperones may have role in AD [30, 31].”
Neurotrophic factors in Alzheimer’s disease: role of axonal transport
Schindowski, K., Belarbi, K., & Buée, L. (2008) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2007.00378.x · Cited by 335
Holsinger, R. M. D., Schnarr, J., Henry, P., Castelo, V. T., & Fahnestock, M. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00023-1 · Cited by 328
Laske, C., Stransky, E., Leyhe, T., Eschweiler, G. W., Maetzler, W., Wittorf, A., Soekadar, S., Richartz, E., Koehler, N., Bartels, M., et al. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.01.014 · Cited by 272
Magrané, J., Smith, R. C., Walsh, K., & Querfurth, H. W. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4330-03.2004 · Cited by 242
Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients
Laske, C., Stellos, K., Hoffmann, N., Stransky, E., Straten, G., Eschweiler, G. W., & Leyhe, T. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001008 · Cited by 180
Yasutake, C., Kuroda, K., Yanagawa, T., Okamura, T., & Yoneda, H. (2006) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-006-0652-8 · Cited by 177
Plasma biomarkers for mild cognitive impairment and Alzheimer's disease
Song, F., Poljak, A., Smythe, G. A., & Sachdev, P. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.003 · Cited by 173
Systemic immune aberrations in Alzheimer's disease patients
Bonotis, K. S., Krikki, E., Holeva, V., Aggouridaki, C., Costa, V., & Balogiannis, S. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.10.020 · Cited by 147
Leyhe, T., Stransky, E., Eschweiler, G. W., Buchkremer, G., & Laske, C. (2007) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0764-9 · Cited by 145
Gunstad, J., Benitez, A., Smith, J., Glickman, E., Spitznagel, M. B., Alexander, T., Juvancic-Heltzel, J., & Murray, L. (2008) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988708316860 · Cited by 144
Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease
Salminen, A., Ojala, J. O., Kaarniranta, K., Hiltunen, M., & Soininen, H. S. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.10.006 · Cited by 142
Blood levels of histamine, IL-1β, and TNF-α in patients with mild to moderate alzheimer disease
Alvarez, X. A., Franco, A., Fernández-Novoa, L., & Cacabelos, R. (1996) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815005 · Cited by 139
Detection of complement alternative pathway mRNA and proteins in the Alzheimer’s disease brain
Strohmeyer, R., Shen, Y., & Rogers, J. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00149-2 · Cited by 124
Cytokines in Alzheimer's Disease and Vascular Dementia
Angelopoulos, P., Agouridaki, H., Vaiopoulos, H., Siskou, E., Doutsou, K., Costa, V., & Baloyiannis, S. I. (2008) · International Journal of Neuroscience · doi:10.1080/00207450701392068 · Cited by 100
Serum tumor necrosis factor (TNF) in Alzheimer's disease and multi-infarct dementia.
Cacabelos, R., Alvarez, X. A., Franco-Maside, A., Fernández‐Novoa, L., & Caamaño, J. C. (1994) · PubMed · Cited by 69
Current therapeutic strategy in Alzheimer's disease.
Singh, S., Kushwah, A. S., Singh, R., Farswan, M., & Kaur, R. (2012) · PubMed · Cited by 54
Honda, S., Itoh, F., Yoshimoto, M., Ohno, S., Hinoda, Y., & Imai, K. (2000) · The Journals of Gerontology Series A · doi:10.1093/gerona/55.5.m265 · Cited by 13
Cited by
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
Lima Giacobbo, B., Doorduin, J., Klein, H. C., Dierckx, R. A. J. O., Bromberg, E., & de Vries, E. F. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1283-6 · Cited by 750
Neuroinflammation in Alzheimer disease
Heneka, M. T., van der Flier, W. M., Jessen, F., Hoozemanns, J., Thal, D. R., Boche, D., Brosseron, F., Teunissen, C., Zetterberg, H., Jacobs, A. H., et al. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01104-7 · Cited by 638
Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Its Pharmaceutical Potential
Gao, L., Zhang, Y., Sterling, K., & Song, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00279-0 · Cited by 606
Cardoso, A. L., Fernandes, A., Aguilar-Pimentel, J. A., de Angelis, M. H., Guedes, J. R., Brito, M. A., Ortolano, S., Pani, G., Athanasopoulou, S., Gonos, E. S., et al. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.07.004 · Cited by 475
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
Metadata
- Authors
- Gezen-Ak, D., Dursun, E., Hanağası, H., Bilgiç, B., Lohman, E., Araz, Ö. S., Atasoy, İ. L., Alaylıoğlu, M., Önal, B., Gürvit, H., & Yılmazer, S.
- Affiliations
- Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
- Istanbul University-Cerrahpaşa (TR)
- Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
- Istanbul University (TR)
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2013-08-20
- Volume
- 37
- Issue
- 1
- Pages
- 185-195
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1612435886
- Cited by
- 188
- References
- 22
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 13 · 2023: 14 · 2022: 12 · 2021: 13 · 2020: 22 · 2019: 16 · 2018: 20 · 2017: 13 · 2016: 18 · 2015: 14 · 2014: 10
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, mild cognitive impairment
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Enzyme-Linked Immunosorbent Assay, Humans, Middle Aged, Regression Analysis, Tumor Necrosis Factor-alpha, Turkey, Cohort Studies, Biomarkers, Case-Control Studies, Interleukin-10, Complement Factor H, Age of Onset, HSP90 Heat-Shock Proteins, Brain-Derived Neurotrophic Factor, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.